Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBT (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed EBT for 6 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 139.11% to $19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$140.1 million through Dec 2025, up 12.89% year-over-year, with the annual reading at -$140.1 million for FY2025, 12.89% up from the prior year.
  • EBT for Q4 2025 was $19.4 million at 4D Molecular Therapeutics, up from -$56.9 million in the prior quarter.
  • The five-year high for EBT was $19.4 million in Q4 2025, with the low at -$56.9 million in Q3 2025.
  • Average EBT over 5 years is -$29.0 million, with a median of -$28.4 million recorded in 2022.
  • The sharpest move saw EBT plummeted 334.17% in 2024, then skyrocketed 139.11% in 2025.
  • Over 5 years, EBT stood at -$25.1 million in 2021, then fell by 9.2% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then surged by 139.11% to $19.4 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $19.4 million, -$56.9 million, and -$54.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.